Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00955396
First received: August 6, 2009
Last updated: January 7, 2010
Last verified: January 2010

August 6, 2009
January 7, 2010
July 2009
December 2009   (final data collection date for primary outcome measure)
Change in 24 h average SBP and DBP from Baseline to Day 36. [ Time Frame: 36 days ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00955396 on ClinicalTrials.gov Archive Site
  • Change in 24 h average SBP and DBP from Baseline to Day 15. Change in average SBP and DBP within a dosing interval (12 h) from Baseline to Days 14 and 35. [ Time Frame: 35 days ] [ Designated as safety issue: Yes ]
  • Change in 24 h average SBP and DBP from Baseline to Days 15 and 36 in subjects with baseline SBP 120-139 mmHg and also DBP 80-89 mmHg. [ Time Frame: 36 days ] [ Designated as safety issue: Yes ]
  • Change in day-time outpatient (6:00 AM to 10:00 PM) SBP and DBP from Baseline to Days 15 and 36. [ Time Frame: 36 days ] [ Designated as safety issue: Yes ]
  • Change in night-time outpatient (10:00 PM to 6:00 AM) SBP and DBP from Baseline to Days 15 and 36. [ Time Frame: 36 days ] [ Designated as safety issue: Yes ]
  • Change in 24 h average ambulatory heart rate from Baseline to Days 15 and 36. [ Time Frame: 36 days ] [ Designated as safety issue: Yes ]
  • Proportion of patients whose 24 h systolic and diastolic BP increased by < 5, 5-9, 1014, 15-19, and > 20 mm Hg compared to baseline. [ Time Frame: 36 days ] [ Designated as safety issue: Yes ]
  • PK parameters of GSK1014802 following a single oral dose of GSK1014802 to healthy female subjects: Cmax, tmax, AUC (0-t) and, if possible, AUC(0-∞), λz and terminal phase half-life to healthy female subjects. [ Time Frame: 1 day ] [ Designated as safety issue: No ]
  • PK parameters of GSK1014802 following repeated oral doses of GSK1014802 given twice daily to healthy male and female subjects: Cmax, tmax, AUC(0-12). [ Time Frame: 36 days ] [ Designated as safety issue: No ]
  • PK/PD analyses to examine the correlation between ambulatory blood pressure and plasma levels and/or metrics of the systemic exposure (Cmax, AUC) of GSK1014802. [ Time Frame: 36 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure
A Randomized, Double-blind, Placebo-controlled Cross-over Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure

In this study the investigators will determine whether there is any effect of GSK1014802 on ambulatory blood pressure. This will be a randomized, double-blind, placebo-controlled, repeat dose, 2 period cross-over study conducted in healthy male and female subjects. Approximately 60 subjects will be randomised to receive GSK1014802 400 mg bid and placebo for 36 days with at least 1 week between treatment sessions. A follow-up will occur 7-14 days after the last dose.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Healthy Volunteer
  • Drug: GSK1014802
    Tablets
  • Drug: Placebo
    Tablets
  • Period 1
    Interventions:
    • Drug: GSK1014802
    • Drug: Placebo
  • Period 2
    Interventions:
    • Drug: GSK1014802
    • Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
December 2009
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female between 18 and 65 years of age inclusive.
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, liver function and cardiac monitoring.
  • A female subject is eligible to participate if she is of:

Non-childbearing potential Child-bearing potential and agrees to use a contraception method.

  • Male subjects must agree to use a contraception methods
  • Body weight ≥ 50 kg and BMI within the range 19 - 40.0 kg/m2 (inclusive).
  • Arm circumference ≥ 24 and ≤ 42 cm at mid level.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • A positive pre-study drug screen.
  • Alcohol levels above the legal limit for driving at screening and the detection of any alcohol within 24 h prior to the start of dosing in Treatment Periods 1 and 2.
  • A positive test for HIV antibody.
  • History of regular excessive alcohol consumption within 6 months of the study
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Use of prescription or non-prescription drugs, including any antihypertensive agent including diuretics, vitamins, herbal and dietary supplements
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period.
  • Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
  • Lactating females.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Subject is mentally or legally incapacitated.
  • Subjects who work at night or whose work schedule includes rotating night time (10:00 PM to 6:00 AM) work.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • Average daily caffeine intake equivalent to > 4 cups of coffee or > 6 cups of tea.
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
  • Consumption of aged cheeses and meats, soy sauce and other tyramine rich sources within 1 day prior to the baseline assessments.
  • Current or past history of symptomatic orthostatic hypotension or history of unexplained vasovagal episode(s).
  • History of known or suspected seizures, including infantile febrile, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits).
  • Any history of suicidal behaviour or suicidal ideation of type 4 or 5 on the C-SSRS within 3 months of the screening visit.
  • History or currently diagnosed sleep apnea.
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00955396
113210
Not Provided
Study Director, GSK
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP